Table 4.
IC50 (μM) | ||||
---|---|---|---|---|
NI-1 | C2 | HMC-1.1 | HMC-1.2 | |
Bosutinib | >2 | >2 | >2 | 0.5–1 |
Dasatinib | <0.003 | 0.003–0.006 | 0.0015–0.003 | 1–2 |
Erlotinib | >2 | >2 | >2 | >2 |
Everolimus | <0.1 | >2 | >2 | >2 |
Gefitinib | >2 | >2 | >2 | >2 |
Imatinib | 0.125–0.25 | 0.025–0.05 | 0.01–0.025 | >2 |
Lapatinib | >2 | >2 | >2 | >2 |
Masitinib | 0.1–0.2 | 0.025–0.05 | 0.005–0.01 | >2 |
Midostaurin | <0.1 | <0.1 | 0.1–0.25 | 0.1–0.25 |
Nilotinib | 0.2–0.3 | 0.1–0.2 | 0.025–0.05 | 1–2 |
NVP-BEZ235 | 0.01–0.05 | 0.01–0.05 | 0.05–0.075 | 0.01–0.05 |
Sunitinib | 0.006–0.013 | 0.006–0.013 | 0.003–0.006 | >2 |
Sorafenib | 0.1–0.25 | 0.005–0.1 | 0.01–0.015 | >2 |
Tozasertib | <0.1 | >2 | >2 | <0.1 |
Vorinostat | 0.1–0.5 | 0.1–0.5 | 0.5–1 | 0.5–1 |
Cells were incubated with various concentrations of targeted drugs at 37°C for 48 h. Then, 3H-thymidine uptake was measured. The mean IC50 values from at least three independent experiments are shown.